Jeff Jensen MD/PhD
@drjensen.bsky.social
📤 7
📥 13
📝 9
I am a lung cancer medical oncologist researching NUT carcinoma and PRAME
reposted by
Jeff Jensen MD/PhD
Society for Immunotherapy of Cancer
about 20 hours ago
Congratulations Dr. Jensen!
0
1
1
Our latest research showing PRAME as a previously unrecognized therapeutic target in NUT carcinoma just dropped on JITC. Huge thanks to
@sitcancer.bsky.social
@benjamingvincent.bsky.social
@alexr.bsky.social
@unclineberger.bsky.social
and so may others!!!
jitc.bmj.com/content/14/2...
loading . . .
Shared PRAME epitopes are T-cell targets in NUT carcinoma
Background NUT carcinoma is a rare but highly lethal solid tumor without an effective standard of care. NUT carcinoma is caused by bromodomain-containing NUTM1 fusion oncogenes, most commonly BRD4::NU...
https://jitc.bmj.com/content/14/2/e013539
about 22 hours ago
1
6
3
@lizbwood.bsky.social
I am an early career physician scientist
@unclineberger.bsky.social
we are trying to open PRAME immunotherapy trials and saw your work
@sitcancer.bsky.social
can we discuss???
@benjamingvincent.bsky.social
@alexr.bsky.social
3 days ago
1
3
0
Congratulations to Zachary Hartman and colleagues
@dukecancer.bsky.social
on their latest paper on CD27 agonists as adjuvants for vaccines. Very cool!
doi.org/10.1126/scii...
loading . . .
CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity
CD27 agonism enhances vaccine-induced CD4 T cell responses, enabling durable antitumor immunity not entirely dependent on CD8 T cells.
https://doi.org/10.1126/sciimmunol.adz2294
about 1 month ago
0
0
0
I thought the breakthrough of the year was PRAME in NUT carcinoma but looks like renewables won instead
www.science.org/content/arti...
loading . . .
Science’s 2025 Breakthrough of the Year: The unstoppable rise of renewable energy
Clean energy infrastructure is being deployed with unmatched scale and speed—and China is leading the way
https://www.science.org/content/article/breakthrough-2025
about 2 months ago
0
0
0
Passed my American Board of Internal Medicine Medical Oncology boards. Woooooo
about 2 months ago
0
1
0
www.fda.gov/drugs/resour...
Great drug but dysgeusia a major draw back
loading . . .
FDA grants traditional approval to tarlatamab-dlle for extensive stage
On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage s
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer
about 2 months ago
0
0
0
Another reason to love trilaciclib: less clonal hematopoiesis. Congratulations to Kelly Bolton Lab for a great study.
doi.org/10.1182/bloo...
loading . . .
CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
AbstractTherapy-related myeloid neoplasms (tMN) are a fatal consequence of exposure to oncologic therapy. Prior work has demonstrated that the expansion of
https://doi.org/10.1182/blood-2025-4
2 months ago
0
0
0
reposted by
Jeff Jensen MD/PhD
Jia (Jenny) Liu MD PhD
3 months ago
Congrats @RashaCosman on late breaking oral presentation, showcasing safety and MOA of novel in vivo CAR targeting TROP2 expressing tumors
#SITC25
@NECTANSW - led trial from 🇦🇺 👏. This technology will expand access to solid tumor cell therapy 🌟
0
5
2
you reached the end!!
feeds!
log in
